PUBLICATIONS: SYSTEMATIC REVIEWS (PEER-REVIEWED)

1. Pergialiotis V, Arnos P, Mavros MN, Pitsouni E, Athanasiou S, Falagas ME. Urinary tract analgesics for the treatment of patients with acute cystitis: where is the clinical evidence? Exp Rev Anti-Infect Ther (in press).
2. Vardakas KZ, Konstantelias AA, Loizidis G, Rafailidis PI, Falagas ME. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis (in press).
3. Michalopoulos A, Falagas ME . Management strategies for the treatment of Gram-negative resistant infections. Exp Opin Pharmacother (in press).
4. Poulikakos P, Tansarli GS, Falagas ME.Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.Eur J Clin Microbiol Infect Dis. 2014  [Epub ahead of print]
5. Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS.Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.Int J Antimicrob Agents. 2014 . pii: S0924-857900020-X.
6. Zarkali A, Karageorgopoulos DE, Rafailidis PI, Falagas ME.Frequency of the off-label use of monoclonal antibodies in clinical practice: a systematic review of the literature.Curr Med Res Opin. 2014;30:471-80.
7. Tansarli GS, Poulikakos P, Kapaskelis A, Falagas ME.Proportion of extended-spectrum β-lactamase (ESBL)-producing isolates among Enterobacteriaceae in Africa: evaluation of the evidence--systematic review.J Antimicrob Chemother. 2014;69:1177-84.
8. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.Antimicrob Agents Chemother. 2014;58:654-63.
9. Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Gkegkes I, Falagas ME.Iron deficiency and susceptibility to infections: evaluation of the clinical evidence.Eur J Clin Microbiol Infect Dis. 2013;32:1253-8.
10. Falagas ME, Karageorgopoulos DE, Leptidis J, Korbila IP.MRSA in Africa: filling the global map of antimicrobial resistance.PLoS One. 2013;8:e68024.
11. Tansarli GS, Athanasiou S, Falagas ME. Evaluation of antimicrobial susceptibility of Enterobacteriaceae causing urinary tract infections in Africa.Antimicrob Agents Chemother. 2013;57:3628-39.
12. Tansarli GS, Kostaras EK, Athanasiou S, Falagas ME.Prevalence and treatment of aerobic vaginitis among non-pregnant women: evaluation of the evidence for an underestimated clinical entity.Infect Eur J Clin Microbiol Dis. 2013;32:977-84.
13. Tansarli GS, Rafailidis PI, Papazoglou AA, Falagas ME.Antimicrobial activity and clinical effectiveness of sisomicin: an evaluation of the literature (1995-2011). Expert Rev Anti Infect Ther 2013;11:421-8.
14. Mavros MN, Mitsikostas PK, Alexiou VG, Peppas G, Falagas ME. Antimicrobials as an adjunct to pilonidal disease surgery: a systematic review of the literature. Eur J Clin Microbiol Infect Dis 2013;32:851-8.
15. Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther 2013;11:321-31.
16. Vardakas KZ, Kontopidis I, Gkegkes ID, Rafailidis PI, Falagas ME. Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review. Eur J Clin Microbiol Infect Dis 2013;32:711-21.
17. Michalopoulos AS, Falagas ME. Inhaled antibiotics in mechanically ventilated patients. Minerva Anestesiol. 2014;80:236-44.
18. Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ. Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review. Expert Rev Anti Infect Ther. 2013;11:69-78.
19. Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME. Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti Infect Ther. 2012 Dec;10:1383-92.
20. Agrafiotis M, Vardakas KZ, Gkegkes ID, Kapaskelis A, Falagas ME. Ventilator-associated sinusitis in adults: Systematic review and meta-analysis. Respir Med  2012 Apr 19. [Epub ahead of print].
21. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012 Mar 5. [Epub ahead of print].
22. Cai Y, Chai D, Falagas ME, Vouloumanou EK, Wang R, Guo D, Bai N, Liang B, Liu Y. Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial. J Antibiotics 2012;65:175-8.
23. Falagas ME, Karageorgopoulos DE, Georgantzi GG, Sun S, Wang R, RafailidisPI. Susceptibility of Gram-negative bacteria to isepamicin: a systematic review. Exp Rev Anti-Infect Ther 2012;10:207-18.
24. Mantadakis M, Plessa E, Vouloumanou EK, Michailidis L, Chatzimichael A, Falagas ME. Deep Venous Thrombosis in Children with Musculoskeletal Infections: the clinical evidence. Int J Infect Dis 2012;16:e236-43.
25. Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacologic considerations for the proper clinical use of aminoglycosides. Drugs 2011;71:2277-94.
26. Vouloumanou EK, Karageorgopoulos DE, Rafailidis PI, Michalopoulos A, Falagas ME. Trimethoprim-sulfametrol: evaluation of the available clinical and pharmacokinetic/pharmacodynamic evidence. Int J Antimicrob Agents 2011;38:197-216.
27. Makris MC, Polyzos KA, Mavros MN, Athanasiou S, Rafailidis PI, Falagas ME. Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review. Drug Safety 2012;35:1-14.
28. Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: The clinical evidence. J Women’s Health 2011;20:1245-55.
29. Mavros MN, Athanasiou S, Gkegkes ID, Polyzos KA, Peppas G, Falagas ME. Do psychological variables affect early surgical recovery? PLoS One 2011;6:e20306.
30. Mavros MN, Velmahos GC, Falagas ME. Atelectasis as a cause of postoperative fever: Where is the clinical evidence? Chest 2011 Apr 28. [Epub ahead of print].
31. Falagas ME, Thomaidis PC, Kotsantis IK, Sgouros K, Samonis G, Karageorgopoulos DE. Airborne hydrogen peroxide for disinfection of the hospital environment and infection control: a systematic review. J Hosp Infect 2011;78:171-7.
32. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria: a review of the published evidence. Eur J Clin Pharmacol 2010;66:359-68.
33. Angelousi AG, Karageorgopoulos DE, Kapaskelis AM, Falagas ME. Association between thyroid function tests at baseline and the outcome of patients with sepsis or septic shock: a systematic review. Eur J Endocrinol 2011;164:147-55.
34. Falagas ME, Koletsi PK, Baskouta E, Rafailidis PI, Dimopoulos G, Karageorgopoulos DE. 2009 (H1N1) pandemic influenza: review of the Southern hemisphere experience. Epidemiol Infect 2011;139:27-40.
35. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010;14:e954-66.
36. Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME. Chronic bacterial and parasitic infections and cancer: a review. J Infect Dev Countries 2010;4:267-81.
37. Falagas ME, Cholevas NV, Kapaskelis AM, Vouloumanou EK, Michalopoulos A, Rafailidis PI. Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the Northern Hemisphere. Eur J Clin Microbiol Infect Dis 2010;29:1327-47.
38. Falagas ME, Kouranos VD, Athanassa Z, Kopterides P. Tuberculosis and malignancy. QJM 2010;103:461-87.
39. Kakisi OC, Kechagia AS, Kakisis IC, Rafailidis PI, Falagas ME. Tuberculosis of the oral cavity: A systematic review. Eur J Oral Sci 2010;118:103-9.
40. Falagas ME, Vouloumanou EK, Baskouta E, Rafailidis PI, Polyzos K, Rello J. Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Int J Antimicrob Agents 2010;35:421-30.
41. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including ESBL-producing, Enterobacteriaceae infections: a systematic review of microbiological and clinical studies. Lancet Infect Dis 2010;10:43-50.
42. Agrafiotis M, Siempos II, Falagas ME. Frequency, prevention, outcome, and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Resp Med 2010;104:325-36.
43. Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI,  Kapaskelis AM, Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol 2009;4:1103-9.
44. Makris GC, Makris MC, Wilmot VV, Geroulakos G, Falagas ME. The role of infection in carotid plaque pathogenesis and stability: the clinical evidence. Curr Vasc Pharmacol 2010 Feb 25. [Epub ahead of print].
45. Falagas ME, Athanasoulia AP, Peppas G, Karageorgopoulos DE. Effect of body mass index on the outcome of infections: A systematic review. Obesity Rev 2009;10:280-9.
46. Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME. Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents 2009;34:197.
47. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 2009;33:503.
48. Kelesidis T, Karageorgopoulos DK, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug resistant Enterobacteriaceae: a review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008;62:895-904.
49. Agrafiotis M, Siempos II, Falagas ME. Infections related to airway stenting: a systematic review. Respiration 2009;78:69-74.
50. Avgeri SG, Matthaiou DK, Dimopoulos G, Grammatikos AP, Falagas ME. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents 2009;33:394-404.
51. Vliagoftis H, Kouranos VD, Betsi G, Falagas ME. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Alergy Asthma Immunol 2008;101:570-9.
52. Falagas ME, Grigori T, Ioannidou E. Trends in the methodological quality of randomized controlled trials in various research fields: a systematic review. J Clin Epidemiol 2009;62:227-31.
53. Grammatikos AP, Siempos II, Michalopoulos A, Falagas ME. Optimal duration of the antimicrobial treatment of ventilator assocaited pneumonia (VAP): evaluation of the current evidence. Exp Rev Anti-Infect Ther 2008;6:861-6.
54. Vouloumanou EK, Rafailidis PI, Kazantzi MS, Athanasiou S, Falagas MF. Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. Curr Med Res Opin 2008;24:3423-34.
55. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy versus combination therapy: evidence from microbiological, animal, and clinical studies. Clin Microbiol Infect 2008;14:816-27.
56. Falagas ME, Valkimadi E, Huang Y, Matthaiou DK, Hsueh P. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole. J Antimicrob Chemother 2008;62:889-94.
57. Falagas ME, Zarkadoulia E. Factors associated with suboptimal compliance to vaccinations in children in developed countries: a systematic review. Curr Med Res Opin 2008;24:1719-41.
58. Mourtzoukou EG, Iavazzo C, Falagas ME. Resiniferatoxin in the treatment of interstitial cystitis: a systematic review. Int Urogynecol J 2008;19:1571-6.
59. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia. J Antimicrob Chemother 2008;62:661-8.
60. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline as treatment for multidrug resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother2008;62:45-55.
61. Rafailidis PI, Matthaiou DI, Varbobitis I, Falagas ME. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol 2008 Mar 5. [Epub ahead of print].
62. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: A systematic review. Virol J 2008;5:47.
63. Falagas ME, Rafailidis PI, Makris GC. Bacterial interference for the prevention and treatment of infections. Int J Antimicrob Agents 2008;31:518-22.
64. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary and gastrointestinal tract infections. Clin Infect Dis 2008;46:1069-77.
65. Falagas ME, Athanasiou S, Iavazzo C, Tokas T, Antsaklis A. Urinary tract infections after pelvic floor gynecological surgery: prevalence and effect of antimicrobial prophylaxis. A systematic review. Int Urogynecol J 2008 [Epub ahead of print].
66. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diab Res Clin Pract 2008;80:344-51.
67. Falagas ME, Rafailidis PI, Makris GC. Bacterial interference for the prevention and treatment of infections. Int J Antimicrob Agents 2008;31:518-22.
68. Mourtzoukou EG, Pappas G, Peppas G, Falagas ME. Vaccination of asplenic or hyposplenic adults. Br J Surg 2008;95:273-80.
69. Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol 2008;9:93-103.
70. Peppas G, Alexiou VG, Mourtzoukou E,  Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008;8:5.
71. Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology 2008;5:13.
72. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008;61:774-85.
73. Iavazzo C, Pitsouni E, Athanasiou S, Falagas ME. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int J Gyn Obstet 2008;101:3-10.
74. Tsiodras S, Kelesidis T, Kelesidis I, Falagas ME. Human infections associated with migratory birds: a systematic review. J Infection 2008;56:83-98.
75. Falagas ME, Vardakas KZ, Samonis G. Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials. Curr Med Res Opin 2008;24:215-35.
76. Falagas ME, Kazantzi MS, Bliziotis IA. Comparison of utility of blood cultures from intravascular catheters and peripheral veins: a systematic review and decision analysis. J Med Microbiol 2008;57:1-8.
77. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities and differences with colistin (polymyxin E). Expert Rev Anti-Infect Ther 2007;5:811-21.
78. Falagas ME, Karveli EA, Siempos II, Vardakas KZ. Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect 2008;136:1009-19.
79. Falagas ME, Voidonikola PT, Angelousi AG. Tuberculosis in patients with systemic rheumatic and pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents 2007;30:477-86.
80. Vardakas KZ, Siempos II, Falagas ME. Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. Diabetic Med 2007;24:1168-71.
81. Korbila PI, Bliziotis IA, Lawrence KR, Falagas ME. Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current evidence. Expert Rev Anti-Infect Ther 2007;5:639-52.
82. Kopterides P, Mourtzoukou EG, Skopelitis H, Tsavaris N, Falagas ME. Aspects of the association between leishmaniasis and malignant disorders. Trans Royal Soc Trop Med 2007;101:1181-1189.
83. Falagas ME, Zarkadoulia EA, Ioannidou EN, Peppas G, Christodoulou C, Rafailidis PI. The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Res 2007;9:R44.
84. Peppas G, Bliziotis IA, Oikonomaki D, Falagas ME. Outcomes after medical and surgical treatment of diverticulitis: A systematic review of the available evidence. J Gastroenterol Hepatol 2007;22:1360-8.
85. Falagas ME,Bliziotis IA. Albendazole for the treatment of human echinococcosis: A review of comparative clinical trials. Am J Med Sci 2007;334:171-9.
86. Bliziotis IA, Ntziora F, Lawrence KR, Falagas ME. Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials. Eur J Clin Microbiol Infect Dis 2007;26:849-56.
87. Falagas ME, Vardakas KZ, Vergidis PI. Under-diagnosis of common chronic diseases: prevalence and impact on human health. Int J Clin Practice 2007;61:1569-79.
88. Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Community-acquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis 2007;26:857-68.
89. Mourtzoukou E, Falagas ME. Exposure to cold and respiratory tract infections. Int J Tuberc Lung Dis 2007;11:938-43.
90. Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. Resp Med 2007;101:1845-63.
91. Falagas ME, Bliziotis IA, Rafailidis PI. Do high doses of quinolones decrease the emergence of antibacterial resistance? A systematic review of data from comparative clinical trials. J Infection 2007;55:97-105.
92. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteremia: a systematic review of the experimental and clinical evidence. J Antimicrob Agents 2007;30:202-9.
93. Falagas ME, Nikou SA, Siempos II. Infections related to coils used for embolization of arteries: a review of the published evidence. J Vasc Interv Radiol 2007;18:697-701.
94. Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 2007;60:214-36.
95. Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infection: a systematic review. Int J Tuberg Lung Dis 2007;11:606-11.
96. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 2007;30:202-9.
97. Falagas ME, Velakoulis S, Iavazzo C, Athanasiou S. Mesh-related infections after pelvic organ prolapse repair surgery: a review. Eur J Obstet Gyn Rep Biol 2007;134:147-56.
98. Rafailidis PI, Kakisi OK, Vardakas KZ, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007;109:2182-9.
99. Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 2007;51:1534-40.
100. Falagas ME, Bliziotis IA. Pandrug-resistantGram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007;29:630-6.
101. Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Contr 2007;35:106-14.
102. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007;41:296-308.
103. Falagas ME, Kasiakou SK. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Infection 2007;35:3-10.
104. Falagas ME, Matthaiou DK, Bliziotis IA. Systematic review: fluoroquinolones for the treatment of intra-abdominal surgical infections. Aliment Pharmacol Ther 2007;25:123-31.
105. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007;29:233-9.
106. Falagas ME, NtzioraF, BetsiGI, Samonis G. Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials. Int J Antimicrob Agents 2007;29:136-43.
107. Falagas ME, Vardakas KZ, Athanasiou S. Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review. Eur J Pharmacol 2007;557:93-8.
108. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins for patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007;29:9-25.
109. Falagas ME,Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheum 2007;26:663-70.
110. FalagasME, SiemposII, BliziotisIA, PanosGZ. Impact of initial discordant treatment with β-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin Proc 2006;81:1567-74.
111. FalagasME, KoletsiPK, BliziotisIA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55:1619-29.
112. Panos GZ, BetsiGI, Falagas ME. Are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharm Ther2006;55:537-8.
113. Falagas ME, Kopterides P. Risk factors for the isolation of multidrug resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006;64:7-15.
114. Falagas ME, MantaKG, Ntziora F, VardakasKZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006;58:273-80.
115. Falagas ME, Betsi GI, Tokas T, Athanasiou S. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs 2006;66:1253-1261.
116. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006;6:438-446.
117. Falagas ME, Apostolou KE, PappasVD. Attributable mortality of candidemia: A systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006;25:419-25.
118. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a critical review of the evidence from old and recent studies. Crit Care 2006;10:R27.
119. Falagas ME, Bliziotis IA, Siempos
120. Falagas ME,Bliziotis IA. Quinolones for the treatment of human brucellosis: A critical review of the evidence from microbiological and clinical studies. Antimicrobial Agents and Chemotherapy 2006;50:22-33.
121. Kasiakou SK, Lawrence KR, Choulis N, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics with time-dependent anti-bacterial action: A systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 2005;65:2499-511.